|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
EP0318554B2
(en)
|
1987-05-21 |
2005-01-12 |
Micromet AG |
Targeted multifunctional proteins
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
FR2650598B1
(fr)
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
AU643109B2
(en)
|
1990-12-14 |
1993-11-04 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
FR2686901A1
(fr)
|
1992-01-31 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
ATE427968T1
(de)
|
1992-08-21 |
2009-04-15 |
Univ Bruxelles |
Immunoglobuline ohne leichtkette
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
HUT76369A
(en)
|
1994-07-29 |
1997-08-28 |
Smithkline Beecham Corp |
Novel soluble protein compounds
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
SE9603936D0
(sv)
|
1996-10-25 |
1996-10-25 |
Sandvik Ab |
Method of making cemented carbide by metal injection molding
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
WO1998056906A1
(en)
|
1997-06-11 |
1998-12-17 |
Thoegersen Hans Christian |
Trimerising module
|
|
ATE386802T1
(de)
|
1997-06-12 |
2008-03-15 |
Novartis Int Pharm Ltd |
Künstliche antikörperpolypeptide
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
|
EP1803730A1
(en)
|
2000-04-12 |
2007-07-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
WO2002092780A2
(en)
|
2001-05-17 |
2002-11-21 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
|
EP1407770B1
(en)
*
|
2001-06-26 |
2013-06-05 |
Takeda Pharmaceutical Company Limited |
Tgf-beta superfamily production/secretion promoter
|
|
EP1435986B1
(en)
*
|
2001-09-18 |
2008-01-02 |
Bioexpertise, Llc |
Igf-binding protein-derived peptide
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
|
EP2990053A1
(en)
|
2004-01-20 |
2016-03-02 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
|
CA2905125C
(en)
|
2004-04-13 |
2017-02-07 |
Samuel Norbert Breit |
Use of mic-1 or modulating agent thereof to modulate appetite or body weight
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
WO2010048670A1
(en)
*
|
2008-10-31 |
2010-05-06 |
St Vincent's Hospital Sydney Limited |
Method of prognosis in chronic kidney disease
|
|
DK2424895T3
(en)
*
|
2009-04-27 |
2017-12-18 |
Novartis Ag |
Compositions and Methods for Increasing Muscle Growth
|
|
KR101838786B1
(ko)
*
|
2012-09-26 |
2018-03-15 |
율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 |
성장 및 분화 인자 15 (gdf-15)에 대한 모노클로날 항체
|
|
JP6758832B2
(ja)
*
|
2012-12-21 |
2020-09-30 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｇｄｆ１５抗体
|
|
GB2524553C
(en)
*
|
2014-03-26 |
2017-07-19 |
Julius-Maximilians-Universitãt Würzburg |
Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
|
|
LT3653644T
(lt)
*
|
2014-03-26 |
2024-01-25 |
Julius-Maximilians-Universität Würzburg |
Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
|
|
US20170137505A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
|
WO2015196145A1
(en)
|
2014-06-20 |
2015-12-23 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
|
|
US20170204149A1
(en)
|
2014-06-23 |
2017-07-20 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
WO2016049470A1
(en)
*
|
2014-09-25 |
2016-03-31 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|